Delivery Order SPE2DB20D3101-SPE2DB23FREX0
- Not listed
- This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Lamictal XR 200 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $16,876.38, is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., which is valued at up to $999,999,999.00 and runs through December 2025. This IDC serves as the primary vehicle for Cencora, Inc. to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $6,583.60, is for the delivery of Lamictal XR 100 mg tablets. This is a firm fixed-price delivery order contract with a period of performance through March 13, 2024. The contract is not designated as a set-aside and was awarded under full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,954.36 firm fixed-price delivery order is for the supply of LAMICTAL XR 300 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of March 10, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued up to $31,762.42, is for the delivery of Lamictal XR 100 mg tablets to the federal government. Amerisourcebergen, as a subsidiary of Amerisourcebergen Corporation, has significant expertise in pharmaceutical supply chain management and has received numerous federal contracts to provide a wide range of...
- This federal contract award, valued at $2,804.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Lamictal XR 25 mg tablets, a neurological medication, and is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $30,993.81 firm fixed-price delivery order is for the pharmaceutical product Lamictal XR 100 mg Tablet 30s, with a period of performance through December 22, 2023. Amerisourcebergen is the prime contractor for this order, which is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,493.27 firm fixed-price delivery order is for the supply of LAMICTAL XR 200 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 30, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award, valued at $27,121.67, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order for the medication Lamictal XR 200 mg tablets and has a completion date of January 31, 2024. The contract is a firm fixed-price arrangement and was not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Medical Supply Chain division of the Department of Defense to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $15,482.55 firm fixed price delivery order is for the supply of Lamictal XR 200 mg tablets. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the Defense Logistics Agency (DLA) Troop Support Medical, which serves as the primary vehicle for the company to...
- The Defense Logistics Agency (DLA) awarded a $8,517.56 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to supply LAMICTAL XR 100 mg tablets. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FREX0Delivery Order
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Lamictal XR 50 mg tablets. The $3,990.19 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which runs through November 2026. This IDC enables Amerisourcebergen to efficiently deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical healthcare commodities to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract award does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation valued at up to $750,000 through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 3/10/23 |